SpringWorks Entered into a Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat + REGN5458 for Multiple Myeloma
Shots:
- The companies collaborated to evaluate SpringWorks’ nirogacestat (gamma-secretase inhibitor) + Regeneron’s REGN5458 in patients with r/r MM
- Regeneron will lead the clinical development & will be responsible for all costs associated with the study other than expenses related to the manufacturing & supply of nirogacestat along with expenses related to IPR
- In preclinical models, nirogacestat can increase the levels of membrane-bound BCMA & reduce levels of soluble BCMA to enhance the activity of BCMA-targeted therapies including CD3 bispecific Abs. Nirogacestat is being studied in a P-III trial for desmoid tumors & has received ODD from the US FDA for desmoid tumors & from the EC for STS
Ref: Globe Newswire | Image: Springworks
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
